Kennedy Capital Management LLC Sells 22,792 Shares of Mesa Laboratories, Inc. $MLAB

Kennedy Capital Management LLC trimmed its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 20.1% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 90,479 shares of the medical instruments supplier’s stock after selling 22,792 shares during the period. Kennedy Capital Management LLC’s holdings in Mesa Laboratories were worth $8,525,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MLAB. Avantax Advisory Services Inc. grew its position in Mesa Laboratories by 22.4% in the 1st quarter. Avantax Advisory Services Inc. now owns 2,036 shares of the medical instruments supplier’s stock valued at $242,000 after acquiring an additional 373 shares during the last quarter. US Bancorp DE boosted its stake in shares of Mesa Laboratories by 48.3% during the first quarter. US Bancorp DE now owns 1,323 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 431 shares during the period. Vanguard Group Inc. grew its holdings in shares of Mesa Laboratories by 0.5% in the first quarter. Vanguard Group Inc. now owns 384,613 shares of the medical instruments supplier’s stock worth $45,638,000 after purchasing an additional 1,757 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Mesa Laboratories by 4.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 65,464 shares of the medical instruments supplier’s stock worth $7,768,000 after buying an additional 2,875 shares during the period. Finally, Herald Investment Management Ltd lifted its holdings in Mesa Laboratories by 68.5% during the 1st quarter. Herald Investment Management Ltd now owns 12,500 shares of the medical instruments supplier’s stock valued at $1,483,000 after buying an additional 5,083 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on MLAB. Wells Fargo & Company raised shares of Mesa Laboratories from an “underweight” rating to an “equal weight” rating and lowered their price objective for the company from $100.00 to $67.00 in a research report on Thursday, August 7th. Wall Street Zen upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Mesa Laboratories in a research note on Wednesday, October 8th. Finally, Zacks Research raised Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $67.00.

Mesa Laboratories Stock Up 1.0%

Shares of NASDAQ MLAB opened at $77.15 on Friday. Mesa Laboratories, Inc. has a 12-month low of $55.45 and a 12-month high of $155.12. The stock’s fifty day simple moving average is $74.34 and its two-hundred day simple moving average is $79.60. The stock has a market capitalization of $425.87 million, a PE ratio of -241.09 and a beta of 0.90. The company has a current ratio of 2.02, a quick ratio of 1.44 and a debt-to-equity ratio of 0.95.

Mesa Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Friday, November 28th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, November 28th. Mesa Laboratories’s payout ratio is -200.00%.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.